0001144204-12-045891.txt : 20120814
0001144204-12-045891.hdr.sgml : 20120814
20120814170540
ACCESSION NUMBER: 0001144204-12-045891
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120630
FILED AS OF DATE: 20120814
DATE AS OF CHANGE: 20120814
EFFECTIVENESS DATE: 20120814
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC
CENTRAL INDEX KEY: 0001263508
IRS NUMBER: 134093645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-10519
FILM NUMBER: 121034104
BUSINESS ADDRESS:
STREET 1: 667 MADISON AVE
STREET 2: 21ST FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10065
BUSINESS PHONE: 2123395600
MAIL ADDRESS:
STREET 1: 667 MADISON AVE
STREET 2: 21ST FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10065
13F-HR
1
v321324_13f.txt
13F-HR
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 13F
FORM 13F COVER PAGE
Report for the Calendar Year or Quarter Ended: June 30, 2012
Check here if Amendment [ ]; Amendment Number: _____
This Amendment (Check only one.): [ ] is a restatement.
[ ] adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: Baker Bros. Advisors, LLC
--------------------------------------------
Address: 667 Madison Avenue, 21st Floor
--------------------------------------------
New York, NY 10065-8029
--------------------------------------------
Form 13F File Number: 28-10519
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables, are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Leo Kirby
--------------------------------------------
Title: Chief Financial Officer
--------------------------------------------
Phone: 212-339-5633
--------------------------------------------
Signature, Place, and Date of Signing:
/s/ Leo Kirby New York, N.Y. August 13, 2012
-------------------------- --------------------------- -------------------
[Signature] [City, State] [Date]
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[_] 13F NOTICE. (Check here if no holdings reported are in this report, and
all holdings are reported by other reporting manager(s).)
[_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported
by other reporting manager(s).)
List of Other Managers Reporting for this Manager: None
FORM 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 0
-----------
Form 13F Information Table Entry Total: 68
-----------
Form 13F Information Table Entry Value: $4,236,374
-----------
(thousands)
List of Other Included Managers: None
Baker Brothers Form 13F 06-30-12
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
-------------- ----- ------- ------- --- ---- ---------- -------- ---- ------ ----
1 Acadia Pharmaceuticals Inc. COM 004225108 9,234 5,246,312 SH SOLE 5,246,312
2 Aegerion Pharmaceuticals COM 00767E102 9,119 614,485 SH SOLE 614,485
3 Alere COM 01449J105 3,402 175,000 SH SOLE 175,000
4 Amicus Therapeutics COM 03152W109 4,208 765,072 SH SOLE 765,072
5 Anacor Pharmaceuticals COM 32420101 3,687 568,130 SH SOLE 568,130
6 Anthera Pharmaceuticals COM 03674U102 810 1,198,339 SH SOLE 1,198,339
7 Aradigm Corp. COM 038505301 12 100,000 SH SOLE 100,000
8 Ariad Pharmaceuticals Inc. COM 04033A100 100,186 5,821,411 SH SOLE 5,821,411
9 Arqule Inc. COM 04269E107 511 86,167 SH SOLE 86,167
10 Array Biopharma Inc. COM 04269X105 3,470 1,000,000 SH SOLE 1,000,000
11 Auxilium COM 05334D107 168,182 6,254,457 SH SOLE 6,254,457
12 Avanir Pharmaceuticals COM 05348P401 1,960 500,000 SH SOLE 500,000
13 Aveo Pharmaceuticals COM 053588109 2,079 171,000 SH SOLE 171,000
14 Biocryst Pharmaceuticals Inc. COM 09058V103 22,088 5,563,615 SH SOLE 5,563,615
15 Biodel Inc. COM 09064M204 1,393 540,000 SH SOLE 540,000
16 BioDelivery Sciences Intl. Inc. COM 09060J106 11,626 2,595,044 SH SOLE 2,595,044
17 Biomarin Pharmaceuticals COM 09061G101 7,933 200,432 SH SOLE 200,432
18 Cerus COM 157085101 4,203 1,266,114 SH SOLE 1,266,114
19 Chelsea Therapeutics COM 163428105 4,495 3,037,402 SH SOLE 3,037,402
20 Chemocentryx Inc. COM 16383L106 750 50,000 SH SOLE 50,000
21 Clovis Oncology COM 189464100 25,387 1,170,991 SH SOLE 1,170,991
22 Cyclacel Pharmaceuticals Pfd.
Conv. Ex 6% PFD CONV EX 23254L207 52 20,979 SH SOLE 20,979
23 Cubist Pharmaceuticals Inc. COM 229678107 190 5,000 SH SOLE 5,000
24 Cumberland Pharmaceuticals COM 230770109 153 23,627 SH SOLE 23,627
25 Derma Sciences COM 249827502 11,508 1,208,857 SH SOLE 1,208,857
26 Discovery Laboratories Inc. COM 254668403 2,378 1,025,000 SH SOLE 1,025,000
27 Exelixis Inc. COM 30161Q104 10,996 1,988,483 SH SOLE 1,988,483
28 Genomic Health Inc. COM 37244C101 374,200 11,203,588 SH SOLE 11,203,588
29 Gilead Sciences Inc. COM 375558103 37,963 740,300 SH SOLE 740,300
30 Halozyme Therapeutics Inc. COM 40637H109 11,866 1,339,245 SH SOLE 1,339,245
31 Idera Pharmaceuticals Inc. COM 45168K108 306 288,252 SH SOLE 288,252
32 Incyte Corp. COM 45337C102 336,200 14,810,559 SH SOLE 14,810,559
33 Infinity Pharmaceuticals Inc. COM 45665303 1,872 138,070 SH SOLE 138,070
34 Ligand Pharmaceuticals Inc. CLASS B 53220K207 1,243 73,400 SH SOLE 73,400
35 Medivation Inc. COM 58501N101 44,171 483,273 SH SOLE 483,273
36 Onyx COM 683399109 14,256 214,543 SH SOLE 214,543
37 Pharmacyclics Inc. COM 716933106 624,976 11,444,360 SH SOLE 11,444,360
38 QLT, Inc. COM 746927102 2,683 352,130 SH SOLE 352,130
39 Raptor Pharmaceuticals COM 75382F106 558 100,000 SH SOLE 100,000
40 Repros Therapeutics COM 76028H209 3,493 384,669 SH SOLE 384,669
41 Rigel Pharmaceuticals COM 766559603 920 98,919 SH SOLE 98,919
42 Seattle Genetics Inc. COM 812578102 490,609 19,322,947 SH SOLE 19,322,947
43 Sequenom Inc. COM 817337405 2,387 587,850 SH SOLE 587,850
44 Spectrum COM 84763A108 38,900 2,500,010 SH SOLE 2,500,010
45 Synageva Biopharma Corp. COM 87159A103 303,287 7,477,464 SH SOLE 7,477,464
46 Synergy Pharmaceuticals COM 871639308 5,273 1,110,000 SH SOLE 1,110,000
47 Synta Pharmaceuticals COM 87162T206 1,709 312,471 SH SOLE 312,471
48 Targacept Inc. COM 87611R306 1,748 406,532 SH SOLE 406,532
49 Threshold Pharma COM 885807107 16,576 2,240,048 SH SOLE 2,240,048
50 Tranzyme COM 89413J102 14,453 3,843,941 SH SOLE 3,843,941
51 Ventrus Biosciences, Inc. COM 922822101 2,053 480,696 SH SOLE 480,696
52 Vertex Pharmaceuticals, Inc. COM 92532F100 45,340 810,794 SH SOLE 810,794
53 Viropharma Inc. COM 928241108 268,660 11,335,878 SH SOLE 11,335,878
54 Xenoport COM 98411C100 4,887 809,112 SH SOLE 809,112
55 Xoma Corp. COM 98419J107 46,345 15,551,915 SH SOLE 15,551,915
56 YM Biosciences COM 984238105 11,753 5,905,791 SH SOLE 5,905,791
57 Ziopharm Oncology Inc. COM 98973P101 2,380 400,000 SH SOLE 400,000
58 Alere Inc. Conv. Notes 3%
5/15/16 CONV BONDS 01449JAA3 4,030 4,482,000 PRN SOLE 4,482,000
59 Biomarin Pharmaceuticals Notes
1.875% 4/23/2017 CONV BONDS 09061GAD3 46,726 22,898,000 PRN SOLE 22,898,000
60 Gilead 1.625% 5/1/16 CONV BONDS 375558AP8 27,910 21,500,000 PRN SOLE 21,500,000
61 Incyte Genomics Notes 4.75%
10/1/2015 CONV BONDS 45337CAH5 417,073 157,758,000 PRN SOLE 157,758,000
62 Intermune Inc Notes 2.5% 9/15/18 CONV BONDS 45884XAE3 17,093 21,500,000 PRN SOLE 21,500,000
63 Intermune Inc Notes 5% 3/1/15 CONV BONDS 45884XAD5 36,463 33,860,000 PRN SOLE 33,860,000
64 Medivation 2.625% 4/1/17 CONV BONDS 58501NAA9 29,247 24,500,000 PRN SOLE 24,500,000
65 Salix 5.5% 8/15/28 CONV BONDS 795435AB2 132,584 22,250,000 PRN SOLE 22,250,000
66 Salix 2.75% 5/15/15 CONV BONDS 795435AC0 150,101 110,572,000 PRN SOLE 110,572,000
67 Salix 144A 1.5% 3/15/19 CONV BONDS 795435AD8 237,818 222,000,000 PRN SOLE 222,000,000
68 Vertex Pharmaceuticals Notes
3.35% 10/1/15 CONV BONDS 92532FAN0 16,250 12,500,000 PRN SOLE 12,500,000
----------
4,236,374
==========